Fig. 5: The mevalonate pathway controls nutrient uptake.
From: The mevalonate coordinates energy input and cell proliferation
a Lovastatin treatment suppresses glucose uptake and lactate acid production, while exogenous MVA recovered the level of glucose and lactate acid to that of the no-treatment group. RKO cells are treated with lovastatin (5 μM) or lovastatin plus MVA (0.5 mM) for 48 h, then the medium is harvested for glucose and lactate acid determination. b Lovastatin treatment suppresses 2-DG uptake in RKO cells, while exogenous MVA recovered it. The cells are treated as described in the Method section. c Lovastatin treatment suppresses amino acid uptake, while exogenous MVA recovered the amino acid level to that of the no-treatment group. RKO cells are treated with lovastatin (5 μM) or lovastatin plus MVA (0.5 mM) for 48 h, then the medium is harvested for amino acid determination by mass spectrometry analysis. d, e MVA itself stimulates glucose uptake and lactate acid production in RKO and SW480 cells. RKO or SW480 cells are cultured in no serum RPMI-1640 medium and supplemented with or without MVA (0.5 mM) for 36 h and the medium is harvested for glucose and lactate acid determination. f MVA increases β-catenin and TAZ protein in energy stressed RKO cells. RKO cells are cultured in an energy stress condition (cultured in Hank’s solution, with 5.5 mM glucose) supplemented with or without MVA (0.5 mM) for 12 h and the cells are harvested for western blot assays. Data are expressed as means ± SEM. *P < 0.05 (LOVA versus L + MVA; NT versus MVA)
